Osimertinib plus anlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer with concurrent gene alterations: A single-arm, prospective, multicenter phase II study. Safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results